Postprandial glucagon-like peptide 1 secretion is associated with urinary albumin excretion in newly diagnosed type 2 diabetes patients

doi:10.4239/wjd.v14.i3.279

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2568)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

151

WORD

HTML

1264

Figures (1-2)

305

Tables (1-3)

188

Sum=1935

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

138

Download

495

Sum=633

Mar 15, 2023 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Diabetes. Mar 15, 2023; 14(3): 279-289
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.279

Table 1 Baseline characteristics

Variable	Newly diagnosed type 2 diabetes			P value
Variable	Total	UACR < 30 mg/g	UACR ≥ 30 mg/g	P value
Number	760	595	165
Age, yr	50.5 ± 9.1	50.3 ± 9.1	51.1 ± 9.6	0.306
Sex, %				0.234
Female	306 (40.1)	232 (38.8)	74 (44.3)	0.212
BMI, kg/m²	25.5 ± 2.6	25.4 ± 2.6	25.7 ± 2.7	0.281
Waist circumference, cm	89.4 ± 8.4	89.2 ± 8.4	90.1 ± 8.2	0.226
SBP, mmHg	123.7 ± 13.1	122.7 ± 12.8	127.2 ± 13.4	< 0.001
DBP, mmHg	79.1 ± 8.5	78.4 ± 8.4	81.3 ± 8.7	< 0.001
eGFR, mL/min	105.6 ± 54.8	103.5 ± 31.9	112.6 ± 98.3	0.052
HbA1c, %	7.5 ± 1.1	7.5 ± 1.2	7.6 ± 1.3	0.804
TG, mmol/L	2.4 ± 2.4	2.3 ± 2.2	2.7 ± 2.9	0.058
HDL-C, mmol/L	1.2 ± 0.3	1.2 ± 0.3	1.2 ± 0.3	0.812
LDL-C, mmol/L	3.1 ± 0.9	3.0 ± 0.9	3.1 ± 1.0	0.508
HOMA-IR	4.0 (2.5-6.3)	3.8 (2.5-6.1)	4.9 (3.1-7.4)	< 0.001
HOMA-β	49.2 (29.0-76.2)	48.1 (28.1-74.4)	53.0 (32.9-81.4)	0.086
LnUACR	2.34 ± 1.51	1.82 ± 1.26	4.16 ± 0.65	< 0.001
RAS inhibitor/RASR blocker use	34 (4.4)	25 (4.2)	9 (5.4)	0.431

Values are expressed as means ± SD, median (interquartile range) or n (%). BMI: Body mass index; DBP: Diastolic blood pressure; eGFR: Evaluated glomerular filtration rate; HbA1c: Hemoglobin A1c; HOMA-IR: Homeostasis model assessment-insulin resistance; HOMA-β: Homeostasis model assessment-β; HDL-c: High density lipoprotein cholesterol; LDL-c: Low density lipoprotein; LnUACR: Natural logarithm of urinary albumin-to-creatinine ratio; SBP: Systolic blood pressure; TG: Triglyceride; RAS: Renin angiotensin system; RASR: Renin angiotensin system receptor; UACR: Urinary albumin-to-creatinine ratio.

Table 2 Mean differences [B (95% confidence interval)] in urinary albumin-to-creatinine ratio among the quartiles of plasma glucagon-like peptide 1 levels in all type 2 diabetes mellitus patients

Variable	Q1	Q2	Q3	Q4	P value
30 min GLP-1	0.24-7.8	7.81-14.3	14.33-27.24	27.31-89.48
Number	191	196	187	186	-
LnUACR	2.58 ± 1.37	2.62 ± 1.30	2.34 ± 1.47	1.85 ± 1.75	-
Model 0	0-reference	-0.036 (-0.333 to 0.261)	-0.214 (-0.516 to 0.088)	-0.746 (-1.046 to -0.445)^a	< 0.001
Model 1	0-reference	-0.022 (-0.314 to 0.271)	-0.213 (-0.510 to 0.084)	-0.772 (-1.069 to -0.476)^a	< 0.001
Model 2	0-reference	0.086 (-0.223 to 0.395)	-0.152 (-0.460 to 0.155)	-0.708 (-1.017 to -0.399)^a	< 0.001
120 min GLP-1	0.03-7.13	7.18-13.6	13.61-25.97	26.0-98.36
Number	194	190	193	183	-
LnUACR	2.57 ± 1.54	2.59 ± 1.22	2.23 ± 1.52	2.01 ± 1.65	-
Model 0	0-reference	-0.030 (-0.272 to 0.331)	-0.330 (-0.632 to -0.028)^a	-0.517 (-0.822 to -0.213)^a	0.001
Model 1	0-reference	-0.051 (-0.247 to 0.350)	-0.270 (-0.567 to 0.028)	-0.456 (-0/758 to -0.155)^a	< 0.001
Model 2	0-reference	0.169 (-0.142 to 0.480)	-0.332 (-0.639 to -0.025)^a	-0.431 (-0.744 to -0.119)^a	< 0.001
AUCGLP-1	175.1-734.2	313.7-1736.3	2817.0-4454.6	4510.2-11877.2
Number	193	192	189	186	-
LnUACR	2.80 ± 1.24	2.49 ± 138	2.25 ± 1.51	1.86 ± 1.72	-
Model 0	0-reference	-0.331 (-0.630 to -0.033)	-0.528 (-0.827 to -0.229)	-0.920 (-1.220 to -0.619)^a	< 0.001
Model 1	0-reference	-0.251 (-0.547 to 0.045)	-0.496 (-0.794 to -0.198)^a	-0.869 (-1.168 to -0.569)^a	< 0.001
Model 2	0-reference	-0.231 (-0.539 to 0.077)	-0.446 (-0.757 to -0.135)^a	-0.860 (-1.169 to -0.552)^a	< 0.001

^aP < 0.05.

Values are presented as range, number, means ± SD, or mean difference (95% confidence interval). Model 0: Crude; Model 1: Adjusted for age, sex, body mass index, systolic blood pressure, diastolic blood pressure, statins medication, evaluated glomerular filtration rate and glycosylated hemoglobin; Model 2: Additionally adjusted for homeostasis model assessment of insulin resistance, area under the glucose curve and area under the glucagon curve. GLP-1: Glucagon-like peptide 1; UACR: Urinary albumin-creatinine ratio; LnUACR: Natural logarithm of urinary albumin-to-creatinine ratio; AUCGLP-1: Area under the curve for active glucagon-like peptide 1.

Table 3 The association between glucagon-like peptide 1 levels during a standard meal test and the urinary albumin-creatinine ratio

Variable	Q1	Q2	Q3	Q4	P value
30 min GLP-1
Microalbuminuria	48 (25.4)	47 (24.6)	42 (23.2)	29 (15.3)
Model 0	1-reference	0.959 (0.603-0.525)	0.828 (0.516-1.330)	0.529 (0.317-0.884)^a	0.014
Model 1	1-reference	0.962 (0.599-1.543)	0.817 (0.505-1.322)	0.517 (0.307-0.873)^a	0.012
Model 2	1-reference	0.967 (0.600-1.557)	0.826 (0.507-1.346)	0.534 (0.315-0.905)^a	0.018
120 min GLP-1
Microalbuminuria	51 (26.8)	42 (22.2)	41 (21.4)	32 (16.8)
Model 0	1-reference	0.779 (0.487-1.245)	0.740 (0.642-1.186)	0.552 (0.336-0.908)^a	0.022
Model 1	1-reference	0.798 (0.495-1.286)	0.775 (0.480-1.251)	0.585 (0.353-0.969)^a	0.044
Model 2	1-reference	0.826 (0.508-1.343)	0.819 (0.504-1.331)	0.592 (0.355-0.988)^a	0.056
AUCGLP-1
Microalbuminuria	52 (27.4)	51 (25.3)	37 (18.9)	32 (15.8)
Model 0	1-reference	0.891 (0.568-1.417)	0.620 (0.383-1.006)	0.498 (0.301-0.823)^a	0.002
Model 1	1-reference	0.973 (0.610-1.552)	0.640 (0.391-1.048)	0.528 (0.316-0.883)^a	0.005
Model 2	1-reference	1.015 (0.632-1.630)	0.704 (0.426-1.161)	0.547 (0.325-0.920)^a	0.010

^aP < 0.05.

Values are presented as range, number, means ± SD, or mean difference (95% confidence interval). Model 0: Crude; Model 1: Adjusted for age, sex, body mass index, systolic blood pressure, diastolic blood pressure, statins medication, evaluated glomerular filtration rate and glycosylated hemoglobin; Model 2: Additionally adjusted for homeostasis model assessment of insulin resistance, area under the glucose curve and area under the glucagon curve. GLP-1: Glucagon-like peptide 1; AUCGLP-1: Area under the curve for active glucagon-like peptide 1.

Citation: Song LL, Wang N, Zhang JP, Yu LP, Chen XP, Zhang B, Yang WY. Postprandial glucagon-like peptide 1 secretion is associated with urinary albumin excretion in newly diagnosed type 2 diabetes patients. World J Diabetes 2023; 14(3): 279-289
URL: https://www.wjgnet.com/1948-9358/full/v14/i3/279.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i3.279